Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
Methods of use, formulations, and devices for delivering therapeutic drugs locally to the region of the spleen are described herein. A method for treating sepsis and other inflammatory disease conditions can include inserting a drug delivery system inside the body, advancing the device to the spleen through the splenic artery, splenic vein or other blood vessel adjacent to the splenic nerves, or within a ligament associated with the spleen, such as the splenorenal or gastrosplenic ligaments.
1. A method of modulating inflammation in a patient, comprising:
providing a therapeutic agent delivery system comprising at least one therapeutic agent, wherein the at least one therapeutic agent is configured to provide an anti-inflammatory effect;
accessing between one or more folds of one or more ligaments directly connected to a splenic hilum of the patient, accessing between the one or more folds of the one or more ligaments comprising:
inserting a catheter into a first blood vessel;
advancing the catheter into a second blood vessel; and
penetrating a wall of the second blood vessel with a portion of the catheter to a position between the one or more folds of the one or more ligaments,
wherein the one or more ligaments comprises at least one of a splenorenal ligament or a gastrosplenic ligament of the patient; and
delivering the therapeutic agent delivery system between the one or more folds of the one or more ligaments, the therapeutic agent delivery system comprising a hydrogel comprising the at least one therapeutic agent,
wherein the hydrogel comprises an injectable in situ forming hydrogel slurry being configured to limit a spread of the hydrogel beyond the one or more folds of the one or more ligaments.
2. The method of claim 1 , wherein the one or more ligaments comprises the splenorenal ligament.
3. The method of claim 1 , wherein the one or more ligaments comprises the gastrosplenic ligament.
4. The method of claim 1 , wherein the one or more ligaments comprises both the gastrosplenic ligament and the splenorenal ligament.
5. The method of claim 1 , wherein the second blood vessel is selected from the group consisting of: a splenic artery and a splenic vein.
6. The method of claim 1 , wherein delivering the therapeutic agent delivery system comprises delivering an implant comprising a therapeutic agent into the one or more ligaments.
7. The method of claim 6 , wherein the implant after delivery coils around a blood vessel between the one or more folds of the one or more ligaments.
8. The method of claim 1 , wherein delivering the therapeutic agent delivery system comprises delivering a plurality of microspheres into the one or more ligaments.
9. The method of claim 1 , wherein the therapeutic agent comprises nicotine.
10. A method of modulating inflammation of a patient, comprising:
accessing between one or more folds of one or more ligaments directly connected to a splenic hilum of the patient, wherein the one or more ligaments comprises at least one of a splenorenal ligament or a gastrosplenic ligament of the patient; and
flowing a gel comprising a therapeutic agent between the one or more folds of the one or more ligaments such that the one or more folds of the one or more ligaments serves as a boundary and limits a spread of the gel to between the one or more folds of the one or more ligaments,
wherein the therapeutic agent is configured to provide an anti-inflammatory effect, and
wherein the gel comprises an injectable in situ forming hydrogel slurry being configured to limit the spread of the gel beyond the one or more folds of the one or more ligaments.
11. The method of claim 10 , wherein the one or more ligaments comprises the splenorenal ligament.
12. The method of claim 10 , wherein the one or more ligaments comprises the gastrosplenic ligament.
13. The method of claim 10 , wherein the one or more ligaments comprises both the gastrosplenic ligament and the splenorenal ligament.
14. A method of modulating inflammation in a patient, comprising:
providing a therapeutic agent delivery system comprising at least one therapeutic agent, wherein the at least one therapeutic agent is configured to provide an anti-inflammatory effect;
accessing between one or more folds of one or more ligaments directly connected to a splenic hilum of the patient, accessing between the one or more folds of the one or more ligaments comprising:
inserting a catheter percutaneously; and
positioning the catheter between the one or more folds of the one or more ligaments with a portion of the catheter,
wherein the one or more ligaments comprises at least one of a splenorenal ligament or a gastrosplenic ligament of the patient; and
delivering the therapeutic agent delivery system between the one or more folds of the one or more ligaments, the therapeutic agent delivery system comprising a hydrogel comprising the at least one therapeutic agent,
wherein the hydrogel comprises an injectable in situ forming hydrogel slurry being configured to limit a spread of the hydrogel beyond the one or more folds of the one or more ligaments.
15. The method of claim 14 , wherein the one or more ligaments comprises the splenorenal ligament.
16. The method of claim 14 , wherein the one or more ligaments comprises the gastrosplenic ligament.
17. The method of claim 14 , wherein the one or more ligaments comprises both the gastrosplenic ligament and the splenorenal ligament.